Sign in
Taking people in SpainPhase 2

Oral decitabine plus ivosidenib for newly diagnosed acute myeloid leukemia in older adults

Tests oral decitabine with ivosidenib in newly diagnosed acute myeloid leukemia with an IDH1 mutation.

Key facts

Who runs it
Fundacion PETHEMA
Where
Albacete, Alcalá de Henares, Alicante, Burgos, Cáceres, Córdoba, Las Palmas De Gran Canaria, Lugo, Madrid, Málaga, San Cristóbal de La Laguna, Sevilla, and Valencia, SpainSee the 16 sitesAlso in 1 other country, 5 sites
Registry title
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy
Status
Recruiting
Phase
Phase 2
People taking part
62 people, planned
Started
12 Jun 2026
Expected to end
25 Mar 2030
Type of study
Interventional
Record updated
14 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation, who are 60 or older or cannot have intensive chemotherapy.

Age
18 years or older. Adults aged 18 to 60 can join only if other health problems rule out intensive chemotherapy. Age 60 or older can join.
Sex
All sexes can join.
Disease stage
Newly diagnosed acute myeloid leukemia (WHO 2022 criteria). Patients under 70 with favorable-risk AML (ELN) can join only if they are not candidates for standard intensive chemotherapy.
Earlier treatment
No earlier treatment for AML, except hydroxyurea.
Biomarker or test result
IDH1 R132 mutation (checked centrally by PCR and NGS). A local test result can be used after approval of the medical monitor.

Main reasons for not taking part

  • Acute promyelocytic leukemia, or AML or myeloproliferative neoplasm with BCR-ABL1 translocation
  • Known HIV, or hepatitis B or C without an undetectable viral load within 3 months
  • Creatinine clearance below 25 mL/min, or liver tests above the set limits
  • Heart rhythm risk: QTcF of 450 msec or more (bundle branch block is an exception)
  • Any severe uncontrolled infection, or another cancer within 1 year that is not controlled or needs treatment

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Morphological diagnosis of AML (WHO criteria 2022)
  • Female subjects must be either postmenopausal OR permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) OR Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control. Female subjects of childbearing potential must have negative results for pregnancy test performed
  • Male subjects who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception
  • Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures
  • Newly diagnosed AML
  • IDH1 R132 mutations (centrally assessed by PCR and NGS). A patient will be allowed to be included with local result after approval of the medical monitor
  • Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2 if ≥ 60 years of age, or 0 to 3 if ≥ 18 to 60 years
  • Age ≥ 18 years with comorbidities contraindicating intensive chemotherapy; or age ≥ 60 years
  • Patients <70 years, with favorable risk AML according to ELN will be included only if they are not candidates to standard treatment with intensive chemotherapy
  • Adequate renal function as demonstrated by a creatinine clearance ≥ 25 mL/min (calculated by the Cockcroft Gault formula)
  • Adequate liver function as demonstrated by: aspartate aminotransferase (AST) ≤ 5.0 × ULN, alanine aminotransferase (ALT) ≤ 5.0 × ULN, bilirubin ≤ 2.5 × ULN (unless considered to be due to leukemic disease)
  • Subject has a white blood cell count < 30 × 109/L (Hydroxyurea is permitted to meet this criterion)

Who cannot take part

  • Prior therapy for AML (except hydroxiurea)
  • Subject has history of myeloproliferative neoplasm [MPN] with BCR-ABL1 translocation and AML with BCR-ABL1 translocation
  • Subject is known to be positive for HIV (HIV testing is not required)
  • Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required)
  • Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients that in the opinion of the investigator would adversely affect his/her participating in this study
  • Any severe uncontrolled systemic infection
  • Subject has a history of other malignancies within 1 year prior to study entry which is not controlled and/or requiring active therapy which may compromise the administration of IVO and oral decitabine
  • Inadequate liver function as demonstrated by AST or ALT > 5.0 × ULN, or bilirubin > 2.5 × ULN (unless considered to be due to leukemic disease)
  • Subject has a white blood cell count > 30 × 109/L that is not controlled using hydrea or 1 gr/sqm/day per 1 day of cytarabine
  • Patient has a heart rate-corrected QT interval using Fridericia’s method QT for corrected heart rate (QTcF) ≥450 msec or any other factor that increases the risk of QT prolongation or arrhythmic events (e.g., hypokalemia, family history of long QT interval syndrome). Patients with prolonged QTcF interval in the setting of bundle branch block may participate in the trial
  • Creatinine clearance <25 mL/min (calculated by the Cockcroft-Gault formula)
  • Contraindications for IVO or oral decitabine according to the SmPC
  • Genetic diagnosis of acute promyelocytic leukemia

Where in Spain

Also in 1 other country, 5 sites

  • Hospital General Universitario de AlbaceteAlbacete, SpainTaking people
  • Hospital Universitario Principe de AsturiasAlcalá de Henares, SpainTaking people
  • Hospital General Universitario Dr. BalmisAlicante, SpainTaking people
  • Hospital Universitario De BurgosBurgos, SpainTaking people
  • Hospital San Pedro De AlcántaraCáceres, SpainTaking people
  • Hospital Universitario Reina SofiaCórdoba, SpainTaking people
  • El Hospital Universitario De Gran Canaria Dr. NegrinLas Palmas De Gran Canaria, SpainTaking people
  • Hospital Universitario Lucus AugustiLugo, SpainTaking people
  • Hospital Universitario 12 de OctubreMadrid, SpainTaking people
  • Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
  • Hospital Universitario Ramón y CajalMadrid, SpainTaking people
  • Hospital Universitario Virgen de la VictoriaMálaga, SpainTaking people
  • Hospital Universitario de CanariasSan Cristóbal de La Laguna, SpainTaking people
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
  • Hospital Universitario Dr. Peset AleixandreValencia, SpainTaking people
  • Hospital Universitario Y Politecnico La FeValencia, SpainTaking people

About the trial

What the trial wants to find out

To evaluate safety and efficacy (CR/CRi rate) of IVO in combination with oral decitabine, in treatment naïve subjects equal or older than 60 years with acute myeloid leukemia (AML) and IDH1 mutation (or older than 18 with comorbidities precluding an intensive approach with IDH1 mutation).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy
Plain-language title
Oral decitabine plus ivosidenib for newly diagnosed acute myeloid leukemia in older adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
14 September 2026